Cómo integrar la radioterapia estereotáxica fraccionada y el hipofraccionamiento en el manejo del cáncer de pulmón localmente avanzado en la era de la inmunoterapia

Autores/as

  • M. Rico Servicio de Oncología Radioterápica. Complejo Hospitalario de Navarra. Pamplona
  • S. Flamarique Andueza Servicio de Oncología Radioterápica. Complejo Hospitalario de Navarra. Pamplona
  • A. Martín Martínez Servicio de Oncología Radioterápica. Complejo Hospitalario de Navarra. Pamplona
  • M.A. Rodríguez Mendizábal Servicio de Oncología Radioterápica. Complejo Hospitalario de Navarra. Pamplona
  • L. Rosas Gutiérrez Servicio de Oncología Radioterápica. Complejo Hospitalario de Navarra. Pamplona
  • E. Martínez López Servicio de Oncología Radioterápica. Complejo Hospitalario de Navarra. Pamplona

DOI:

https://doi.org/10.23938/ASSN.0855

Palabras clave:

Cáncer de pulmón., Hipofraccionamiento., SBRT., Inmunoterapia.

Resumen

Los constantes avances en el campo de la inmunoterapia en cáncer de pulmón se han visto reflejados en la aprobación de durvalumab para el tratamiento de la enfermedad localmente avanzada tras radioterapia y quimioterapia concurrente. Sin embargo, la radioterapia sigue siendo clave para el control de la enfermedad en este estadio. A lo largo de los años se han utilizado varias estrategias para tratar de optimizar su papel, siendo la toxicidad cardíaca y la pulmonar las principales barreras. En este contexto, el interés por el uso del hipofraccionamiento y la radioterapia estereotáxica fraccionada para el cáncer de pulmón no microcítico estadio III ha ido en aumento. El hipofraccionamiento es un tratamiento relativamente extendido aunque el nivel de evidencia que lo acompaña sea limitado. Por su parte, la radioterapia estereotáxica fraccionada se ha estudiado especialmente como una técnica para sobredosificar áreas concretas de la enfermedad tras el tratamiento con radioquimioterapia. En ambos casos, el estudio de cómo integrar estas herramientas radioterápicas con la quimioterapia, y especialmente con la inmunoterapia, es esencial, dado que pueden jugar además un papel inmunomodulador.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

M. Rico, Servicio de Oncología Radioterápica. Complejo Hospitalario de Navarra. Pamplona

Licenciado en Medicina en 2005

Especialista en Oncología Radioterápica en 2010

Médico Adjunto del Servicio de Oncología Radioterápica del CHN desde 2010

Dedicación al tratamiento del cáncer de pulmón y tumores de SNC

Título de Doctor en el año 2016

Responsable del área de radiocirugía

Citas

National Comprehensive Cancer Network. NCCN Guidelines® & Clinical Resources. Non-Small Cell Lung Cancer 2019; https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

ANTONIA SJ, CHIAPPORI A, GRAY JE, VILLEGAS A, MEKHAIL T, DANIEL D et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018; 379: 2342-2350. http://doi.org/ 10.1056/NEJMoa1809697.

Radiation therapy oncology group RTOG 0617/NCCTG N0628/CALGB 30609/ECOG R0617. A randomized phase III comparison of standard- dose (60 Gy) versus high- dose (74 Gy) conformal radiotherapy with concurrent and consolidation carboplatin/paclitaxel +/- cetuximab (ind #103444) in patients with stage IIIA/IIIB non-small cell lung cancer. https://www.rtog.org/LinkClick.aspx?fileticket=QU8LgXgAimk%3D&tabid=290

POPP I, GROSU AL, NIEDERMANN G, DUDA DG. Immune modulation by hypofractionated stereotactic radiation therapy: therapeutic implications. Radiother Oncol 2016; 120: 185-194. http://dx.doi.org/10.1016/j.radonc.2016.07.013

GOLDSTRAW P, CHANSKY K, CROWLEY J, RAMI-PORTA R, ASAMURA H, EBERHARDT WEE et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11: 39-51. https://doi.org/10.1097/JTO.0000000000000334

SAUNDERS MI, DISCHE S, BARRETT A, PARMAR MKB, HARVEY A, GIBSON D. Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: An interim report. Br J Cancer 1996; 73: 1455-1462. https://doi.org/10.1038/bjc.1996.276

BAUMANN M, HERRMANN T, KOCH R, MATTHIESSEN W, APPOLD S, WAHLERS B et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 2011; 100: 76-85. https://doi.org/10.1016/j.radonc.2011.06.031

MAUGUEN A, LE PÉCHOUX C, SAUNDERS MI, SCHILD SE, TURRISI AT, BAUMANN M et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol 2012; 30: 2788-2797. https://doi.org/10.1200/jco.2012.41.6677

ZHANG W, LIU Q, DONG X, LEI P. A meta-analysis comparing hyperfractionated vs. conventional fractionated radiotherapy in non-small cell lung cancer. J Thorac Dis 2015; 7: 478-485. https://doi.org/ 10.3978/j.issn.2072-1439.2015.02.20

WANG K, EBLAN MJ, DEAL AM, LIPNER M, ZAGAR TM, WANG Y et al. Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy. J Clin Oncol 2017; 35: 1387-1394. https://doi.org/10.1200/jco.2016.70.0229

EATON BR, PUGH SL, BRADLEY JD, MASTERS G, KAVADI VS, NARAYAN S et al. Institutional Enrollment and Survival among NSCLC Patients Receiving Chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617. J Natl Cancer Inst 2016; 108: 1-8. https://doi.org/10.1093/jnci/djw034

CHUN SG, HU C, CHOY H, KOMAKI RU, TIMMERMAN RD, SCHILD SE et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol 2017; 35: 56-62. https://doi.org/10.1200/jco.2016.69.1378

DE RUYSSCHER DKM, BOTTERWECK A, DIRX M, PIJLS-JOHANNESMA M, WANDERS R, HOCHSTENBAG M et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol 2009; 20: 98-102. https://doi.org/10.1093/annonc/mdn559

AL-SHAMSI HO, AL FARSI A, ELLIS PM. Stage III non-small-cell lung cancer: establishing a benchmark for the proportion of patients suitable for radical treatment. Clin Lung Cancer 2014; 15: 274-280. https://doi.org/10.1016/j.cllc.2014.02.003

POSTMUS PE, KERR KM, OUDKERK M, SENAN S, WALLER DA, VANSTEENKISTE J et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (Suppl 4): iv1-iv21. https://doi.org/10.1093/annonc/mdx222

RODRIGUES G, CHOY H, BRADLEY J, ROSENZWEIG KE, BOGART J, CURRAN WJ et al. Adjuvant radiation therapy in locally advanced non-small cell lung cancer: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Pract Radiat Oncol 2015; 5: 149-155. https://doi.org/10.1016/j.prro.2015.02.013

RAMROTH J, CUTTER DJ, DARBY SC, HIGGINS GS, MCGALE P, PARTRIDGE M et al. Dose and fractionation in radiation therapy of curative intent for non-small cell lung cancer : meta-analysis of randomized trials. Radiat Oncol Biol 2016; 96: 736-747. https://doi.org/10.1016/j.ijrobp.2016.07.022

PARTRIDGE M, RAMOS M, SARDARO A, BRADA M. Dose escalation for non-small cell lung cancer: analysis and modelling of published literature. Radiother Oncol 2011; 99: 6-11. https://doi.org/10.1016/j.radonc.2011.02.014

KASTER TS, YAREMKO B, PALMA DA, RODRIGUES GB. Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature. Clin Lung Cancer 2015; 16: 71-79. https://doi.org/10.1016/j.cllc.2014.08.002

CANNON DM, MEHTA MP, ADKISON JB, KHUNTIA D, TRAYNOR AM, TOMÉ WA et al. Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol 2013; 1; 31: 4343-4348. https://doi.org/10.1200/jco.2013.51.5353

PREWETT SL, ASLAM S, WILLIAMS M V., GILLIGAN D. The Management of Lung Cancer: a UK Survey of Oncologists. Clin Oncol 2012; 24: 402-409. https://doi.org/10.1016/j.clon.2012.03.005

COLLINS LG, HAINES C. Lung cancer: diagnosis and management. NICE Guidelines (NG122); March 2019. https://www.nice.org.uk/guidance/ng122

DIN OS, HARDEN S V., HUDSON E, MOHAMMED N, PEMBERTON LS, LESTER JF et al. Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: results from 4 UK centres. Radiother Oncol 2013; 109: 8-12. https://doi.org/10.1016/j.radonc.2013.07.014

MCMENEMIN R, PEEDELL C, MCNEE S, KELLY V, MAGUIRE J, O’ROURKE N et al. SOCCAR: a randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status. Eur J Cancer 2014; 50: 2939-2949. https://doi.org/10.1016/j.ejca.2014.07.009

BELDERBOS J, UITTERHOEVE L, VAN ZANDWIJK N, BELDERBOS H, RODRIGUS P, VAN DE VAART P et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007; 43: 114-121. https://doi.org/10.1016/j.ejca.2006.09.005

WALRAVEN I, VAN DEN HEUVEL M, VAN DIESSEN J, SCHAAKE E, UYTERLINDE W, AERTS J et al. Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab. Radiother Oncol 2016; 118: 442-446. https://doi.org/10.1016/j.radonc.2016.02.011

STAM B, VAN DER BIJL E, VAN DIESSEN J, ROSSI MMG, TIJHUIS A, BELDERBOS JSA et al. Heart dose associated with overall survival in locally advanced NSCLC patients treated with hypofractionated chemoradiotherapy. Radiother Oncol 2017; 125: 62-65. https://doi.org/10.1016/j.radonc.2017.09.004

DE DIOS NR, SANZ X, FORO P, MEMBRIVE I, REIG A, ORTIZ A et al. Accelerated hypofractionated radiation therapy (AHRT) for non-small-cell lung cancer: can we leave standard fractionation? Clin Transl Oncol 2017; 19: 440-447. https://doi.org/10.1007/s12094-016-1544-7

CHOY H, TIMMERMAN RD, SAUNDERS MW, COURT LE, PATEL MK, LI Y et al. A Phase III randomized study of image guided conventional (60 Gy/30 fx) versus accelerated, hypofractionated (60 Gy/15 fx) radiation for poor performance status stage II and III NSCLC Patients-An Interim Analysis. Int J Radiat Oncol 2016; 96: E451. https://doi.org/10.1016/j.ijrobp.2016.06.1763

ROACH MC, BRADLEY JD, ROBINSON CG. Optimizing radiation dose and fractionation for the definitive treatment of locally advanced non-small cell lung cancer. J Thorac Dis 2018; 10 (Suppl 21): S2465-S2473 https://doi.org/10.21037/jtd.2018.01.153

MA L, MEN Y, FENG L, KANG J, SUN X, YUAN M et al. A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer. Radiol Oncol 2019; 53: 6-14. https://doi.org/10.2478/raon-2019-0006

BALL D, MAI GT, VINOD S, BABINGTON S, RUBEN J, KRON T et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol 2019 ;20: 494-503. https://doi.org/10.1016/s1470-2045(18)30896-9

KALMAN NS, WEISS E, WALKER PR, ROSENMAN JG. Local radiotherapy intensification for locally advanced non–small-cell lung cancer - A call to arms. Clin Lung Cancer 2018; 19: 17-26. https://doi.org/10.1016/j.cllc.2017.05.024

KARAM SD, HORNE ZD, HONG RL, MCRAE D, DUHAMEL D, NASR NM. Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer. Radiat Oncol 2013; 8: 1-8. https://doi.org/10.1186/1748-717x-8-179

FEDDOCK J, ARNOLD SM, SHELTON BJ, SINHA P, CONRAD G, CHEN L et al. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer : a prospective study. Radiat Oncol Biol 2013; 85: 1325-1331. https://doi.org/10.1016/j.ijrobp.2012.11.011

KUMAR S, FEDDOCK J, LI X, SHEARER AJ, HALL L, SHELTON BJ et al. Update of a prospective study of stereotactic body radiation yherapy for post-chemoradiation residual disease in stage II / III non-small cell lung cancer. Radiat Oncol Biol 2017; 99: 652-659. https://doi.org/10.1016/j.ijrobp.2017.07.036

HEPEL JT, LEONARD KL, SAFRAN H, NG T, TABER A, KHURSHID H et al. Stereotactic body radiation therapy boost after concurrent chemoradiation for locally advanced non-small cell lung cancer: a phase 1 dose escalation study. Int J Radiat Oncol Biol Phys 2016; 96: 1021-1027. https://doi.org/10.1016/j.ijrobp.2016.08.032

HIGGINS KA, PILLAI RN, CHEN Z, TIAN S, ZHANG C, PATEL P et al. Concomitant chemotherapy and radiotherapy with sbrt boost for unresectable stage III non–small cell lung cancer: a phase I study. J Thorac Oncol 2017; 12: 1687-1695. https://doi.org/10.1016/j.jtho.2017.07.036

KIM YJ, KIM SS, SONG SY, CHOI EK. Feasibility of stereotactic radiotherapy for lung lesions and conventional radiotherapy for nodal areas in primary lung malignancies. Radiat Oncol 2018; 13: 127. https://doi.org/10.1186/s13014-018-1071-5

NGUYEN NTA, ISFAHANIAN N, POND G, HANNA W, CUTZ JC, WRIGHT J et al. A novel neoadjuvant therapy for operable locally invasive non–small-cell lung cancer. Phase I study of neoadjuvant stereotactic body radiotherapy. LINNEARRE I (NCT02433574) Clin Lung Cancer 2017; 18: 436-440. https://doi.org/10.1016/j.cllc.2017.01.007

SINGH AK, HENNON M, MA SJ, DEMMY TL, PICONE A, DEXTER EU et al. A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer. BMC Cancer 2018; 29; 18: 1183. https://doi.org/10.1186/s12885-018-5039-5

LEAMAN ALCIBAR O, CANDINI D, LÓPEZ-CAMPOS F, ALBERT ANTEQUERA M, MORILLO MACÍAS V, CONDE AJ et al. Time for radioimmunotherapy: an overview to bring improvements in clinical practice. Clin Transl Oncol 2019; 21: 992-1004. https://doi.org/10.1007/s12094-018-02027-1

GOLDEN EB, CHHABRA A, CHACHOUA A, ADAMS S, DONACH M, FENTON-KERIMIAN M et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol 2015; 16: 795-803. https://doi.org/10.1016/s1470-2045(15)00054-6

SHAVERDIAN N, LISBERG AE, BORNAZYAN K, VERUTTIPONG D, GOLDMAN JW, FORMENTI SC et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 2017; 18: 895-903. https://doi.org/10.1016/s1470-2045(17)30380-7

TANG C, WELSH JW, DE GROOT P, MASSARELLI E, CHANG JY, HESS KR et al. Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells. Clin Cancer Res 2017; 23: 1388-1396. https://doi.org/10.1158/1078-0432.ccr-16-1432

U. S. National Library of Medicine. ClinicalTrials.gov identifier: NCT03833154. https://clinicaltrials.gov/ct2/show/NCT03833154

U. S. National Library of Medicine. ClinicalTrials.gov identifier: NCT03589547. https://clinicaltrials.gov/ct2/show/NCT03589547

U. S. National Library of Medicine. ClinicalTrials.gov identifier: NCT04003246. https://clinicaltrials.gov/ct2/show/NCT04003246

Descargas

Publicado

2020-08-31

Cómo citar

Rico, M., Flamarique Andueza, S., Martín Martínez, A., Rodríguez Mendizábal, M., Rosas Gutiérrez, L., & Martínez López, E. (2020). Cómo integrar la radioterapia estereotáxica fraccionada y el hipofraccionamiento en el manejo del cáncer de pulmón localmente avanzado en la era de la inmunoterapia. Anales Del Sistema Sanitario De Navarra, 43(2), 225–234. https://doi.org/10.23938/ASSN.0855